Long title
EXACT 2 is a randomized, multicenter, double-blind, placebo-controlled Phase 2b trial designed to evaluate the safety, feasibility, and efficacy of percutaneous endovascular catheter-facilitated intramyocardial administration of XC001 in patients with refractory angina due to coronary artery disease .
Date receipt dossier
EudraCT number
2024-514874-36
Company / Sponsor
XyloCor Therapeutics
Phase
IIb
Treated organism
Humans
Indication category
Cardiovascular therapy
Disease
refractaire angina (RA)
Therapeutic approach
Gene therapy
Genetic modification
VEGF
Method of transfer of nucleic acid of interest
Recombinant adenoviral vector (Ad5)
Administered biological material
Recombinant adenoviral vector (Ad5)
Route of administration
Intramyocardial
Locations in Belgium
UZ Brussel, AZ Delta
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
XC001